Synta Pharma (SNTA), Madrigal Pharma Enter All-Stock Merger Agreement Apr 14, 2016 07:01AM
Synta and Madrigal Announce Merger Agreement to Create Leading Cardiovascular-Metabolic Diseases and NASH Company Apr 14, 2016 07:00AM
Roth Capital Downgrades Synta Pharma. (SNTA) to Neutral; $1 PT Oct 21, 2015 08:41AM
Roth 'Encouraged' by Progress in Phase II GANNET53; Reaffirms Synta (SNTA) at 'Buy' Jun 2, 2015 05:11PM
Synta Pharmaceuticals Closes Public Offering of Common Stock Apr 6, 2015 11:30AM


Mar 31, 2015 09:16AM Synta Pharma (SNTA) Prices 22M Common Offering at $1.75/Share
Feb 6, 2015 10:08AM Roth Cuts PT on Synta Pharma (SNTA) to $20; Still Attractively Priced Given Ganetespib Potential
Dec 12, 2014 02:23PM Roth Affirms Synta Pharma (SNTA) at 'Buy'; Early Ganetespib Data is 'Encouraging'
Nov 6, 2014 02:09PM Roth Capital Positive on Synta (SNTA) Following Q3 Results; Focus Remains on Ganetespib Phase III GALAXY-2
Nov 5, 2014 11:40AM Synta's (SNTA) Ganetespib Could See Extra Exclusivity Following FDA Meeting - Roth
Oct 29, 2014 12:24PM Roth Capital Maintains Synta Pharma (SNTA) at 'Buy; Has Initial Meeting with CEO Whitaker
Aug 6, 2014 02:10PM New CEO Whitaker is Positive for Synta Pharma (SNTA); Roth Affirms at 'Buy' Following Q2 Results
Jun 3, 2014 07:44AM Synta (SNTA) Management Ready to Take Company to Next Level; Roth Affirms 'Buy' Rating
Mar 20, 2014 11:08AM Synta Pharma (SNTA) Positive Trajectory Reinforced by Latest ENCHANT-1 Data - Roth
Mar 4, 2014 09:08AM Near-Term Volatility Expected on Exec Shift, But Fundamentals Inact for Synta Pharma (SNTA) - Roth
Jan 10, 2014 07:50AM Roth Capital Sees Synta Pharma (SNTA) Ganetespib Trial Updates as Positive; Affirms 'Buy' Rating
Nov 18, 2013 10:11AM Synta Pharma (SNTA) Closes 16.1M Common Offering at $3.75/Share
Nov 13, 2013 09:29AM Synta Pharmaceuticals (SNTA) Prices 14M Share Offering at $3.75
May 7, 2013 01:05PM UPDATE: BMO Capital Downgrades Synta Pharma. (SNTA) to Market Perform
May 7, 2013 11:41AM Synta Pharma (SNTA) Sell-Off Related to R&D Pres. Resignation, Could Be Buying Opp
Jan 11, 2012 04:01PM Synta (SNTA) Closes 7M Common Offering for Net Proceeds of ~$28.6M
May 10, 2010 08:09AM Roth Capital Upgrades Synta Pharmaceuticals (SNTA) to Buy; Valuation Call
Feb 17, 2010 08:25AM Roth Capital Downgrades Synta Pharmaceuticals (SNTA) to Hold
Jan 8, 2010 10:37AM Morning Movers 01/08: AEN, CYCC, SPDE, LEI, HTX, LUNA Higher; SNTA, ROG, DMAN, LWSN Lower